Evidence map›Paper›PMID 40421129›Full record

ArticleTherapeutic advances in medical oncology2025

CanAssist Breast-based prognostication in low-intermediate estrogen receptor positive (ER

Susmita Ghosh, Tejal Deepak Durgekar, Manvi Sunder, Badada Ananthamurthy Savitha, Payal Shrivastava, Naveen Krishnamoorthy, Deepti K Shivashimpi, Manjiri M Bakre

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in medical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Susmita GhoshOncoStem Diagnostics Private Limited, Bangalore, Karnataka, India.
Tejal Deepak DurgekarOncoStem Diagnostics Private Limited, Bangalore, Karnataka, India.
Manvi SunderOncoStem Diagnostics Private Limited, Bangalore, Karnataka, India.
Badada Ananthamurthy SavithaOncoStem Diagnostics Private Limited, Bangalore, Karnataka, India.
Payal ShrivastavaOncoStem Diagnostics Private Limited, Bangalore, Karnataka, India.
Naveen KrishnamoorthyOncoStem Diagnostics Private Limited, Bangalore, Karnataka, India.
Deepti K ShivashimpiOncoStem Diagnostics Private Limited, Bangalore, Karnataka, India.
Manjiri M BakreOncoStem Diagnostics Private Limited, 4, Raja Ram Mohan Roy Road, Aanand Towers, 2nd Floor, Bangalore, Karnataka 560027, India.ORCID https://orcid.org/0000-0003-1160-8102

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The estrogen receptor (ER) is one of the key biomarkers in breast cancer (BC), and therapy decisions are based on ER expression levels. However, the benefit of endocrine therapy in patients with ER expression (ER Objective: The study aims to assess whether CanAssist Breast (CAB), an immunohistochemistry-based prognostic test validated globally in ER+/PR+/HER2- early-stage breast cancer (EBC) patients, would help prognosticate ER Design: We conducted secondary data analyses of previously published retrospective studies to evaluate CAB prognostication in ER Methods: Analysis of CAB-based risk stratification was conducted on 2896 ER+/PR+/HER2- EBC patients with a known percentage of ER staining in both ER Results: ER Conclusion: CAB-based risk stratification of ER

Indexed as

breast cancerCanAssist Breastchemotherapyendocrine therapyestrogen receptor-lowprognostication

Identifiers

PMID40421129
PMCPMC12104605

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.